Routine first-trimester pre-eclampsia screening and risk of preterm birth.


Journal

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
ISSN: 1469-0705
Titre abrégé: Ultrasound Obstet Gynecol
Pays: England
ID NLM: 9108340

Informations de publication

Date de publication:
08 2022
Historique:
revised: 04 04 2022
received: 26 02 2022
accepted: 07 04 2022
pubmed: 21 4 2022
medline: 4 8 2022
entrez: 20 4 2022
Statut: ppublish

Résumé

Preterm birth (PTB) is a major public health problem worldwide. It can occur spontaneously or be medically indicated for obstetric complications, such as pre-eclampsia (PE) or fetal growth restriction. The main objective of this study was to investigate whether there is a shared uteroplacental etiology in the first trimester of pregnancy across PTB subtypes. This was a retrospective cohort study of singleton pregnancies that underwent screening for preterm PE as part of their routine first-trimester ultrasound assessment at a tertiary center in London, UK, between March 2018 and December 2020. Screening for preterm PE was performed using the Fetal Medicine Foundation algorithm, which includes maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and pregnancy-associated plasma protein-A (PAPP-A). Women with a risk of ≥ 1 in 50 for preterm PE were classified as high risk and offered prophylactic aspirin (150 mg once a day) and serial ultrasound assessments. The following delivery outcomes were evaluated: PTB < 37 weeks, iatrogenic PTB (iPTB) and spontaneous PTB (sPTB). Logistic regression analyses were performed to assess the association of PTB, iPTB and sPTB with an increased risk of preterm PE. A model for prediction of PTB < 37 weeks and < 33 weeks was developed and its performance was compared with that of an existing model in the literature. A total of 11 437 women were included in the study, of whom 475 (4.2%) had PTB. Of these, 308 (64.8%) were sPTB and 167 (35.2%) were iPTB. Patients with PTB had a higher body mass index, were more likely to be of black or Asian ethnicity, be smokers, have pregestational hypertension or diabetes, or have a history of previous PTB. They also had higher MAP (87.7 vs 86.0 mmHg, P < 0.0001), higher UtA-PI multiples of the median (MoM) (0.99 vs 0.92, P < 0.0001) and lower PAPP-A MoM (0.89 vs 1.08, P < 0.0001) compared to women with a term birth. In women at high risk of PE, the odds ratio for iPTB was 6.0 (95% CI, 4.29-8.43; P < 0.0001) and that for sPTB was 2.0 (95% CI, 1.46-2.86; P < 0.0001). A prediction model for PTB < 37 weeks and < 33 weeks, developed based on this cohort, included previous PTB, black ethnicity, chronic hypertension, diabetes mellitus, PAPP-A MoM and UtA-PI MoM. The performance of the model was similar to that of an existing first-trimester prediction model for PTB < 33 weeks (area under the curve, 0.704 (95% CI, 0.653-0.754) vs 0.694 (95% CI, 0.643-0.746)). Increased first-trimester risk for uteroplacental dysfunction was associated with both iPTB and sPTB, implying a shared etiological pathway. The same factors used to predict PE risk show acceptable discrimination to predict PTB at < 33 weeks. Women at high risk of uteroplacental dysfunction may warrant additional monitoring and management for an increased risk of sPTB. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Identifiants

pubmed: 35441764
doi: 10.1002/uog.24915
pmc: PMC9545360
doi:

Substances chimiques

Biomarkers 0
Placenta Growth Factor 144589-93-5
Pregnancy-Associated Plasma Protein-A EC 3.4.24.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-191

Informations de copyright

© 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Références

Am J Obstet Gynecol. 1993 Feb;168(2):585-91
pubmed: 8438933
Lancet. 2021 Mar 27;397(10280):1183-1194
pubmed: 33773630
BJOG. 2015 Oct;122(11):1484-93
pubmed: 26111589
Clin Kidney J. 2020 Nov 24;14(1):49-58
pubmed: 33564405
J Matern Fetal Neonatal Med. 2009 Dec;22(12):1122-39
pubmed: 19916710
Br J Obstet Gynaecol. 1975 Sep;82(9):702-10
pubmed: 1182090
Am J Obstet Gynecol. 2022 Feb;226(2S):S895-S906
pubmed: 32971013
Placenta. 2013 Jan;34(1):14-9
pubmed: 23199792
Lancet Glob Health. 2019 Jan;7(1):e2-e3
pubmed: 30389450
Ultrasound Obstet Gynecol. 2007 Oct;30(5):742-9
pubmed: 17899573
Lancet. 2008 Jan 5;371(9606):75-84
pubmed: 18177778
Obstet Gynecol. 1997 Feb;89(2):265-71
pubmed: 9015033
Science. 2014 Aug 15;345(6198):760-5
pubmed: 25124429
N Engl J Med. 2017 Aug 17;377(7):613-622
pubmed: 28657417
Am J Obstet Gynecol. 2006 Dec;195(6):1557-63
pubmed: 17014813
BJOG. 2021 Jan;128(2):177-194
pubmed: 32981206
Am J Obstet Gynecol. 2017 Apr;216(4):411.e1-411.e14
pubmed: 28065815
Obstet Gynecol. 2017 Feb;129(2):327-336
pubmed: 28079785
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Am J Obstet Gynecol. 2002 Nov;187(5):1137-42
pubmed: 12439491
Fetal Diagn Ther. 2012;31(1):42-8
pubmed: 22248988
Am J Obstet Gynecol. 2003 Oct;189(4):1063-9
pubmed: 14586356
Ultrasound Obstet Gynecol. 2022 Jan;59(1):55-60
pubmed: 34319638
BJOG. 2019 May;126(6):763-769
pubmed: 30461172
Am J Obstet Gynecol. 2011 Mar;204(3):193-201
pubmed: 21094932
Prenat Diagn. 2011 Jan;31(1):75-83
pubmed: 21210482
BJOG. 2021 Jan;128(2):149-156
pubmed: 32613730
Ultrasound Obstet Gynecol. 2021 Oct;58(4):540-545
pubmed: 33998078
Am J Obstet Gynecol. 2021 Nov;225(5):520.e1-520.e10
pubmed: 33901486
Acta Obstet Gynecol Scand. 2018 Aug;97(8):907-920
pubmed: 29663314

Auteurs

V Giorgione (V)

Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.
Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

O Quintero Mendez (O)

Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

A Pinas (A)

Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

W Ansley (W)

Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

B Thilaganathan (B)

Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.
Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH